Figure 5 illustrates the sensitivity of the test in the combined Development/Internal Validation sets and in the Independent Validation set depending on tumor size in comparison with the detection by applying the 20 ng/mL AFP concentration cut-off. This evidence concerns the gene AFP and neoplasm.